Martin LeBlanc

Papers

1

Total Citations

2

H-Index

1

About

Martin LeBlanc is a nuclear medicine and molecular imaging specialist whose research focuses on the application of prostate-specific membrane antigen (PSMA)-targeted PET/CT in prostate cancer management. His most notable contribution involves the identification and characterization of port-site metastasis following robot-assisted laparoscopic radical prostatectomy, a rare but clinically significant complication of minimally invasive oncologic surgery. In his landmark 2023 case report, LeBlanc documented a 74-year-old patient who developed metastatic disease at surgical access sites despite prior salvage radiotherapy, demonstrating the superior sensitivity of 18F-DCFPyL PET/CT in detecting these unusual recurrences. This work has been cited 2 times and provides critical guidance for clinicians interpreting post-surgical imaging. LeBlanc’s research bridges surgical oncology and advanced molecular imaging, offering practical insights into the natural history of prostate cancer recurrence. His findings underscore the importance of PSMA-targeted imaging in identifying atypical patterns of disease spread, ultimately contributing to more accurate staging and tailored treatment planning for patients with biochemical recurrence.

Research Focus

Key Achievements

1
H-Index
1
Papers
2
Total Citations
2
Avg Citations/Paper
🏆 Most Cited Paper
Port-Site Metastasis Identified on Prostate-Specific Membrane Antigen–Targeted 18F-DCFPyL PET/CT After Robot-Assisted Laparoscopic Radical Prostatectomy
2 citations · 2023
📈 Most Prolific Year: 2023 (1 Papers)
🤝 Key Collaborators: 5

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago